3 July 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
Nanogenics Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide an update on its subsidiary, Nanogenics Limited ("Nanogenics").
Nanogenics has now submitted an application to the U.S. Food and Drug Administration ("FDA") to obtain orphan drug designation for its product ECP105, for the prevention of scarring following glaucoma surgery. Obtaining orphan drug status in the USA is expected to bring substantial cost and time savings on the development work and once approved, seven years of exclusivity. A decision is expected by the FDA three months from the date of application.
Alongside this, Nanogenics has also filed a patent application in the UK for novel siRNA sequences that can be used as part of the ECP105 development work.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"Having orphan drug status for ECP105 in the USA will be akin to getting a patent granted as it provides exclusivity for the treatment indication applied for.
"Alongside applying for orphan drug status in the USA, Nanogenics is strengthening its IP position by filing a patent for novel siRNA sequences which can be used to widen its product protection further."
For more information please contact:
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To hear more, visit |
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/WPGM9e
|
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| | |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
